Cargando…

Short-term effects of lovastatin therapy on proteinuria of type 2 diabetic nephropathy: A clinical trial study

BACKGROUND: Diabetic nephropathy (DN) is characterized by albuminuria, hypertension, and a progressive decline in glomerular filtration rate. The 3-hydroxy-3-methylglutaryl coenzyme A is a well-known agent that is active in lowering total plasma and low-density lipoprotein cholesterol (LDL-C) levels...

Descripción completa

Detalles Bibliográficos
Autores principales: Sadighi, Alireza, Safa, Javid, Vatankhah, Amir-Mansour, Ghorashi, Sona, Aharilahagh, Aida, Davari-Farid, Sina, Nezami-Nargabad, Ourmaan, Naghavi-Behzad, Mohammad, Piri, Reza, Pishahang, Parinaz, Babapoor-Farrokhran, Savalan, Fakour, Sanam, Ghodratnezhad-Azar, Nastaran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036295/
https://www.ncbi.nlm.nih.gov/pubmed/27833243
http://dx.doi.org/10.4103/0300-1652.190600
Descripción
Sumario:BACKGROUND: Diabetic nephropathy (DN) is characterized by albuminuria, hypertension, and a progressive decline in glomerular filtration rate. The 3-hydroxy-3-methylglutaryl coenzyme A is a well-known agent that is active in lowering total plasma and low-density lipoprotein cholesterol (LDL-C) levels in cases with hypercholesterolemia. Hence, in this study, proteinuria changes at the beginning and after the withdrawal of lovastatin in patients with type 2 DN (T2DN) were studied. MATERIALS AND METHODS: Lovastatin was administered for thirty male patients with T2DN and then was withdrawn. Twenty-four hours, urine creatinine and protein levels were determined. RESULTS: The mean levels of total cholesterol and LDL-C were reduced without any change in the triglyceride (TG) level while the high-density lipoprotein cholesterol (HDL-C) level was increased. There was a reverse linear correlation between the changes in the level of HDL-C and the changes in the level of 24 h urine protein after 90 days of lovastatin therapy (P = 0.007, r = −0.484). CONCLUSIONS: Short-term 3-month lovastatin therapy has no effect on proteinuria levels in patients with T2DN despite the antihyperlipidemic effects and reverse correlation of proteinuria with HDL-C.